Stock A145020 HUGEL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Hugel, Inc.

Equities

A145020

KR7145020004

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
208,000 KRW +0.97% Intraday chart for Hugel, Inc. +4.37% +39.22%
Mar. 27 Hugel, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares. CI
Mar. 27 Hugel, Inc. authorizes a Buyback Plan. CI

Business Summary

Hugel Inc is a Korea-based company mainly engaged in the manufacture of biopharmaceuticals. The Company's product portfolio consists of botulinum toxins which used for treatment of benign essential blepharospasm and temporary improvement of moderate to severe glabellar lines including 50 unit types, 100 unit types and 200unit types; hyaluronic acid (HA) fillers which used for temporary removal of facial wrinkles including the chaeum premium No.1, the chaeum premium No.2, the chaeum premium No.3m the chaeum premium No.4, the chaeum MID 20A, the chaeum DEEP 20A, the chaeum SUB-Q 20A and the chaeum VOLUS 20A; wellages, blue roses and other cosmetics. The Company sells its products in domestic and overseas markets.

Number of employees: 562

Sales per Business

KRW in Million2022Weight2023Weight Delta
Toxin
52.7 %
160,777 57.1 % 168,523 52.7 % +4.82%
Filler
37.0 %
94,165 33.4 % 118,393 37.0 % +25.73%
Cosmetics
8.4 %
20,902 7.4 % 26,755 8.4 % +28.01%
Other Medical Devices
1.3 %
3,575 1.3 % 4,285 1.3 % +19.88%
Service, Etc.
0.5 %
2,257 0.8 % 1,744 0.5 % -22.75%

Sales per region

KRW in Million2022Weight2023Weight Delta
South Korea
44.6 %
131,273 46.6 % 142,735 44.6 % +8.73%
Asia
28.6 %
83,004 29.5 % 91,504 28.6 % +10.24%
Europe and Middle East
14.2 %
39,865 14.2 % 45,243 14.2 % +13.49%
Americas
8.6 %
22,926 8.1 % 27,537 8.6 % +20.11%
Others
4.0 %
4,608 1.6 % 12,681 4.0 % +175.22%

Managers

Managers TitleAgeSince
Sun-Ho Han COO
 Chief Operating Officer 59 17-12-31
Dong-Hoon Oh CTO
 Chief Tech/Sci/R&D Officer 52 14-06-30
Chang-Jin Lee CTO
 Chief Tech/Sci/R&D Officer 52 13-02-28
Ji-Hoon Sohn BRD
 Director/Board Member 60 18-06-25
Chul-Min Park HRO
 Human Resources Officer 47 18-08-31
Min-Jong Kang SAM
 Sales & Marketing 48 19-06-30
Soon-Woo Kwon PRN
 Corporate Officer/Principal 54 -

Members of the board

Members of the board TitleAgeSince
Suk-Yong Cha CHM
 Chairman 70 23-03-29
Michael Keyoung
50 -
Han-Soo Keyoung BRD
 Director/Board Member 50 22-03-31
Tae-Hyung Lee BRD
 Director/Board Member 54 22-03-31
Ji-Hoon Sohn BRD
 Director/Board Member 60 18-06-25
Seung-Min Ji BRD
 Director/Board Member 50 22-03-31
Patrick Holt BRD
 Director/Board Member 52 22-03-31
Seo-Hong Heo BRD
 Director/Board Member 47 22-03-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 11,942,329 5,486,927 ( 45.95 %) 1,099,751 ( 9.209 %) 45.95 %

Shareholders

NameEquities%Valuation
Aphrodite Acquisition Holdings LLC
44.58 %
5,355,651 44.58 % 760 M ₩
HUGEL, INC.
9.750 %
1,171,314 9.750 % 166 M ₩
Massachusetts Financial Services Co.
4.761 %
571,970 4.761 % 81 M ₩
MFS International (UK) Ltd.
4.348 %
522,323 4.348 % 74 M ₩
AllianceBernstein Ltd.
0.5973 %
71,764 0.5973 % 10 M ₩
AHAM Asset Management Bhd.
0.4224 %
50,743 0.4224 % 7 M ₩
MFS International Singapore Pte. Ltd.
0.0972 %
11,683 0.0972 % 2 M ₩
Stanley-Laman Group Ltd.
0.0832 %
10,000 0.0832 % 1 M ₩
UBP Asset Management Asia Ltd.
0.0470 %
5,646 0.0470 % 801 449 ₩
BN Securities AB
0.0449 %
5,400 0.0449 % 766 529 ₩

Holdings

NameEquities%Valuation
HUGEL, INC.
9.75%
 1,171,314 9.75% 166,267,858 $
OLIX PHARMACEUTICALS, INC
2.16%
 355,592 2.16% 4,397,852 $

Company contact information

Hugel, Inc.

61-20 Sinbuk-ro Sinbuk-eup

24206, Chuncheon-si

+

http://www.hugel-inc.com/kr
address Hugel, Inc.(A145020)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per Business

Sales per region

Ratings for Hugel, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
208,000 KRW
Average target price
218,778 KRW
Spread / Average Target
+5.18%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
HUGEL, INC. Stock Hugel, Inc.
+39.22% 1.65B
CSL LIMITED Stock CSL Limited
-2.86% 87.31B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.95% 40.86B
BIOGEN INC. Stock Biogen Inc.
-21.94% 29.36B
UCB Stock UCB
+54.44% 24.49B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-5.41% 17.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-44.23% 11.26B
INCYTE CORPORATION Stock Incyte Corporation
-17.60% 11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-13.96% 11.31B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+7.57% 8.31B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A145020 Stock
  4. Company Hugel, Inc.